Oncology Support
Breast and prostate cancer hormone therapies, targeted cancer medicines and a supportive antiemetic make up this range. Nolvadex, Altraz and Aromasin are among the recognised names here.

Tamoxifen Tablets
20mg
Tamoxifen tablets for breast cancer. It blocks oestrogen that some breast cancers rely on to grow.

Methotrexate Tablets
2.5mg · 5mg · 7.5mg · 10mg
Methotrexate tablets for rheumatoid arthritis and psoriasis. It calms the immune system's attack on joints and skin.
Key points
- Cancer medicines here split into two roles: most act directly on a tumour, while a smaller group provides supportive care for treatment effects.
- Efudex is applied topically here, listed for actinic keratosis and superficial basal cell carcinoma rather than a systemic cancer treatment.
- Three of the twelve medicines here, Hydrea, Gleevec and Sprycel, are listed for chronic myeloid leukaemia.
- Methotrexate Tablets is listed for rheumatoid arthritis and psoriasis as well as acute lymphocytic leukaemia, spanning antirheumatic and antineoplastic roles.
Tamoxifen, anastrozole and exemestane for breast cancer
Tamoxifen is the ingredient in both Nolvadex and Tamoxifen Tablets, listed for breast cancer; Nolvadex is also listed under Women’s Health. Anastrozole is the aromatase inhibitor in Altraz, and exemestane is the aromatase inhibitor in Aromasin, each also listed for breast cancer. Casodex contains bicalutamide, an androgen receptor inhibitor listed for prostate cancer.
Targeted therapies and supportive care
Gleevec contains imatinib, also listed for gastrointestinal stromal tumours. Sprycel contains dasatinib, also listed for acute lymphocytic leukaemia. Hydrea contains hydroxycarbamide, also listed for head and neck cancer and sickle cell anaemia. Tarceva contains erlotinib, listed for non-small cell lung cancer and pancreatic cancer. Zofran contains ondansetron, supportive care here for chemotherapy-induced and postoperative nausea and vomiting rather than a tumour-directed treatment.









